Search results for "phosphonate"

showing 10 items of 372 documents

Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment

2010

The importance of adoption of recommendations for ONJ prevention strategy will notably grow for zoledronic acid in the next future, in view of possible further enlargement of its indications (even with different timing and schedules) in breast cancer patients without bone metastases (such as in adjuvant and neo-adjuvant settings, and in hormonotherapy-induced osteopenia

Oncologymedicine.medical_specialtyBreast Neoplasmszoledronic acidBreast cancerSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineHumansBone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawbusiness.industryImidazolesOsteonecrosisGeneral Medicinemedicine.diseaseosteonecrosis jawsZoledronic acidJawbreast cancer patientsFemaleSurgerybusinessOsteonecrosis of the jawmedicine.drugThe Breast
researchProduct

Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: A systematic review

2019

Background: The goal of this paper was to identify available biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw (BRONJ). Material and Methods: Case-control studies comparing the different concentrations of a series of molecules detected in serum and urine as matrices of BRONJ affected patients vs. non-affected were included. PRISMA guidelines for systematic reviews were used for the present paper. Two reviewers independently screened electronic databases (Medline, Web of science, and The Cochrane Library) and performed hand searches. Risk of bias assessment of selected studies was performed by the Newcastle-Ottawa Scale. This study is registered as PROSPERO CR…

Oncologymedicine.medical_specialtyMEDLINEReviewCochrane LibraryRisk Assessment03 medical and health sciences0302 clinical medicineBiphosphonatePredictive Value of TestsInternal medicinemedicineHumansGeneral DentistryOral Medicine and PathologyBisphosphonate-associated osteonecrosis of the jawbusiness.industryCase-control study030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Systematic reviewOtorhinolaryngologyCase-Control Studies030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASBisphosphonate-Associated Osteonecrosis of the JawSurgerybusinessRisk assessmentOsteonecrosis of the jawBiomarkers
researchProduct

Osteonecrosis of the jaws produced by sunitinib : a systematic review

2019

Background Tyrosine kinase receptor family is involved in tumor growth, pathological angiogenesis and the progression (metastasis) of cancer. Sunitinib (Sutent®) inhibits members of the tyrosine kinase receptor family affecting the induction of angiogenesis and tumor progression. It is not clear if sunitinib increases the risk of osteonecrosis of the jaws (ONJ). The aim of this study was to carry out a systematic review about ONJ related to sunitinib, describing existing cases and possible associated risk factors. Material and Methods The PubMed/MEDLINE and Cochrane Library databases were searched without date restriction up to September 2018. We included prospective and retrospective obser…

Oncologymedicine.medical_specialtyPopulationMEDLINEReviewCochrane Library03 medical and health sciences0302 clinical medicineInternal medicineSunitinibmedicineHumansProspective StudieseducationProspective cohort studyGeneral DentistryRetrospective Studieseducation.field_of_studyOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesSunitinibbusiness.industryOsteonecrosisRetrospective cohort study030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Cross-Sectional StudiesDenosumabOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryObservational studybusinessmedicine.drug
researchProduct

Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplem…

2017

To the Editor, In their recent article, Stopeck et al. [1] concluded that denosumab confirms its known safety profile even after longterm exposure, or after switching to it from zoledronic acid, and that osteonecrosis of jaws (ONJ) rates increased with increasing exposure to antiresorptives, consistent with previous reports. This is based on the open label extension phase of two phase 3 studies in patients with breast and prostate cancer with bone metastases who were randomized to receive denosumab or zoledronic acid (ZA) [2, 3]. The patients were offered open-label denosumab for up to an additional 2 years after the results of the primary analysis, favorable for denosumab on several aspect…

Oncologymedicine.medical_specialtyPopulationlaw.invention03 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerRandomized controlled triallawInternal medicineNeoplasmsmedicineHumanseducationLetter to the Editoreducation.field_of_studyBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosisCancer030206 dentistrymedicine.diseaseSurgeryDenosumabZoledronic acidOncology030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawDenosumabOncology osteonecrosis denosumab metastatic cancer patientsbusinessJaw Diseasesmedicine.drug
researchProduct

Reply: 18F-FDG PET for Routine Posttreatment Surveillance in Oral and Oropharyngeal Squamous Cell Carcinoma

2010

1164 Objectives 68Ga-BPAMD (BPAMD = (4-{[bis-(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxy methyl)-1,4,7,10-tetraazacyclododec-1-yl)acetic acid) was used in a first human in vivo study for diagnosis of osteoblastic bone metastases. The DOTA-based bisphosphonate ligand BPAMD may also be suitable for complexation with therapeutic radionuclides such as 177Lu. The same ligand thus may be used for diagnosis, dosimetry calculation, therapy and therapy control via PET/CT. Methods 177Lu was provided in 0.04 M HCl via the 176Yb(n,γ)177Yb→177Lu production process. Labelling was studied using different amounts of ligand in acetate buffer at pH 4-5 and different temperatures. For quality control…

Oncologymedicine.medical_specialtybiologyChemistrymedicine.medical_treatmentPharmacologyBisphosphonateLigand (biochemistry)Acetic acidchemistry.chemical_compoundFarnesyl diphosphate synthaseIn vivoLabellingInternal medicineRadionuclide therapymedicinebiology.proteinDOTARadiology Nuclear Medicine and imagingJournal of Nuclear Medicine
researchProduct

Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery : an institution's experience

2020

Background Dentoalveolar surgery is a predisposing factor for medication related osteonecrosis of the jaw (MRONJ). The aim of our study was to evaluate the described surgical procedures to prevent the development of MRONJ after dentoalveolar surgery in patients receiving bisphosphonates. Material and methods In this retrospective study, sixty-three dentoalveolar surgeries were performed on 44 patients taking bisphosphonate in accordance with the treatment procedures we described. The following procedures were applied to patients 1) use of antibiotics 2) performed dentoalveolar surgical procedures 3) fill the socket with leukocyte- and platelet-rich fibrin (L-PRF) 4) post-operative applicati…

Oral Medicine and Pathologybusiness.industrymedicine.medical_treatmentResearchDentistryDentoalveolar surgeryRetrospective cohort study030206 dentistryPreventive DentistryBisphosphonatemedicine.disease:CIENCIAS MÉDICAS [UNESCO]03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASmedicineIn patientbusinessOsteonecrosis of the jawRisk assessmentGeneral DentistryLow level laser therapy
researchProduct

Breathing effect in a cobalt phosphonate upon dehydration/rehydration: a single-crystal-to-single-crystal study.

2013

Two cobalt phosphonates, [Co2(2,2′-bpy)2(H2O)(pbtcH)] (1) and [Co2(H2O)(pbtcH)(phen)2] (2; pbtcH5=5-phosphonatophenyl-1,2,4-tricarboxylic acid, 2,2′-bpy=2,2′-bipyridine, phen=1,10-phenanthroline), with layer structures are reported. Compound 1 contains O-C-O and O-P-O bridged tetramers of Co4, which are further connected by pbtcH(4-) units to form a layer. In compound 2, the cobalt tetramers made up of water-bridged Co2 dimers and O-P-O linkages are connected into a layer by pbtcH(4-) units. Upon dehydration, compounds 1 and 2 experience single-crystal-to-single-crystal (SC-SC) structural transformations to form [Co2(2,2′-bpy)2(pbtcH)] (1 a) and [Co2(pbtcH)(phen)2] (2 a), respectively. The …

Organic Chemistrychemistry.chemical_elementGeneral Chemistrymedicine.diseaseCrystal engineeringPhosphonateCatalysischemistry.chemical_compoundCrystallographychemistryFerromagnetismmedicineAntiferromagnetismMoleculeDehydrationCobaltSingle crystalChemistry (Weinheim an der Bergstrasse, Germany)
researchProduct

Differential Effects of Tenofovir/Emtricitabine and Abacavir/Lamivudine on Human Leukocyte Recruitment

2012

Background The association of abacavir (ABC) with cardiovascular disease has led to HIV treatment guidelines favouring the combination of tenofovir/emtricitabine (TDF/FTC) over that of ABC/lamivudine (ABC/3TC). We have analysed the effects of plasma-relevant concentrations of TDF, FTC, ABC and 3TC, individually and in clinically employed combinations, on human leukocyte accumulation. The effects of ABC, 3TC, TDF and FTC on the expression of adhesion molecules were also evaluated. Methods Interactions between human leukocytes – specifically peripheral blood polymorphonuclear or mono-nuclear cells – and human umbilical vein endothelial cells were evaluated in a flow chamber reproducing in viv…

OrganophosphonatesHIV InfectionsCD18Cell CommunicationPharmacologyEmtricitabineDeoxycytidinePeripheral blood mononuclear cellIn vivoAbacavirAntiretroviral Therapy Highly ActiveCell AdhesionLeukocytesmedicineEmtricitabineHumansPharmacology (medical)TenofovirPharmacologyCell adhesion moleculebusiness.industryAdenineEndothelial CellsLamivudineAbacavir/LamivudineDideoxynucleosidesDrug CombinationsInfectious DiseasesLamivudinebusinessCell Adhesion Moleculesmedicine.drugAntiviral Therapy
researchProduct

Nonexposed Variant of Bisphosphonate-associated Osteonecrosis of the Jaw: A Case Series

2010

Abstract Purpose To report a case series of patients with the nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw—a form of jaw osteonecrosis that does not manifest with necrotic bone exposure/mucosal fenestration. Methods Among 332 individuals referred to 5 clinical centers in Europe because of development of jawbone abnormalities after or during exposure to bisphosphonates, we identified a total of 96 patients who presented with the nonexposed variant of osteonecrosis. Relevant data were obtained via clinical notes; radiological investigations; patients' history, and referral letters. Results The most common clinical feature of nonexposed osteonecrosis was jaw bone pa…

OsteochemonecrosisMaleTime FactorsAvascular necrosisMandibleAvascular necrosiEpidemiologyMaxillaProspective cohort studyMultiple myelomaAged 80 and overeducation.field_of_studyAlendronateBone Density Conservation AgentsDiphosphonatesOsteochemonecrosiOsteonecrosisGeneral MedicineBisphosphonatesMiddle AgedKidney NeoplasmsEuropeAvascular necrosisFemaleMultiple MyelomaAdultmedicine.medical_specialtyPopulationJawsBreast NeoplasmsSettore MED/28 - Malattie OdontostomatologicheJawbonesmedicineHumansBisphosphonateeducationAgedBisphosphonate-associated osteonecrosis of the jawbusiness.industryProstatic NeoplasmsAvascular necrosis; Bisphosphonates; Jawbones; Jaws; Mandible; Maxilla; Osteochemonecrosis; Osteonecrosismedicine.diseaseDermatologySurgeryJawMaxillaOsteoporosisJawbonebusinessOsteonecrosis of the jawJaw Diseases
researchProduct

Follow-up of non-exposed ONJ related to bisphosphonate: a two-year study

2015

Aim. Osteonecrosis of the jaw (ONJ) is a serious sideeffect of amine bisphosphonate (NBP) and/or other antiresorptive agents frequently used in the management of osteometabolic and cancer-related condition. The traditional ONJ definition exclude patients who present the non-exposed variant. However, according to recent data, staging and monitoring of ONJ should be closely linked to clinical and radiological manifestation regardless of the presence of bone exposed. The aim of this study was a descriptive analysis of a case series of patients with non-exposed ONJ (exclusively related to NBP) monitoring for two years. Methods. From 2012 to 2014, 16 patient [7 oncological (F/M=3/4; mean age=66,…

Osteonecrosis JAW bisphosphonate antiresorptive
researchProduct